1
|
Xavier-Ferrucio J, Ricon L, Vieira K, Longhini AL, Lazarini M, Bigarella CL, Franchi G, Krause DS, Saad STO. Hematopoietic defects in response to reduced Arhgap21. Stem Cell Res 2017; 26:17-27. [PMID: 29212046 PMCID: PMC6084430 DOI: 10.1016/j.scr.2017.11.014] [Citation(s) in RCA: 18] [Impact Index Per Article: 2.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/27/2017] [Revised: 11/13/2017] [Accepted: 11/20/2017] [Indexed: 12/28/2022] Open
Abstract
Arhgap21 is a member of the Rho GTPase activating protein (RhoGAP) family, which function as negative regulators of Rho GTPases. Arhgap21 has been implicated in adhesion and migration of cancer cells. However, the role of Arhgap21 has never been investigated in hematopoietic cells. Herein, we evaluated functional aspects of hematopoietic stem and progenitor cells (HSPC) using a haploinsufficient (Arhgap21+/-) mouse. Our results show that Arhgap21+/- mice have an increased frequency of phenotypic HSC, impaired ability to form progenitor colonies in vitro and decreased hematopoietic engraftment in vivo, along with a decrease in LSK cell frequency during serial bone marrow transplantation. Arhgap21+/- hematopoietic progenitor cells have impaired adhesion and enhanced mobilization of immature LSK and myeloid progenitors. Arhgap21+/- mice also exhibit reduced erythroid commitment and differentiation, which was recapitulated in human primary cells, in which knockdown of ARHGAP21 in CMP and MEP resulted in decreased erythroid commitment. Finally, we observed enhanced RhoC activity in the bone marrow cells of Arhgap21+/- mice, indicating that Arhgap21 functions in hematopoiesis may be at least partially mediated by RhoC inactivation.
Collapse
Affiliation(s)
- Juliana Xavier-Ferrucio
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil; Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.; Yale Stem Cell Center, Yale School of Medicine, New Haven, CT, USA
| | - Lauremília Ricon
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil
| | - Karla Vieira
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil
| | - Ana Leda Longhini
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil
| | - Mariana Lazarini
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil; Department of Biological Sciences, Federal University of São Paulo, Diadema, Brazil
| | - Carolina Louzão Bigarella
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil
| | - Gilberto Franchi
- Onco-Hematological Child Research Center (CIPOI), Faculty of Medical Sciences, University of Campinas-UNICAMP, Campinas, SP, Brazil
| | - Diane S Krause
- Department of Laboratory Medicine, Yale School of Medicine, New Haven, CT, USA.; Yale Stem Cell Center, Yale School of Medicine, New Haven, CT, USA
| | - Sara T O Saad
- Hematology and Blood Transfusion Center University of Campinas/Hemocentro-UNICAMP, Instituto Nacional de Ciência e Tecnologia do Sangue, Campinas, SP, Brazil.
| |
Collapse
|